Cytokinetics, Incorporated — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Cytokinetics is a late-stage biopharmaceutical company developing muscle-directed medicines. It had no commercial product sales during the year.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Total revenue | $7.5 million | $94.6 million |
| Research and development expense | $330.1 million | $240.8 million |
| General and administrative expense | $173.6 million | $178.0 million |
| Operating loss | $496.2 million | $324.2 million |
| Net loss | $526.2 million | $389.0 million |
| Net loss per share | $5.45 | $4.33 |
| Net cash used in operating activities | $414.3 million | $299.5 million |
Revenue declined principally because FY 2022 included $87.0 million recognized upon extinguishment of the mavacamten royalty obligation; FY 2023 revenue was primarily collaboration reimbursements and a $2.5 million Ji Xing milestone. R&D spending rose 37%, mainly reflecting cardiac program clinical activity and other development costs. G&A declined modestly. The company reported no commercial-sales revenue and has an accumulated deficit of approximately $2.1 billion.
At year-end, cash, cash equivalents and investments totaled approximately $655.4 million, down from $829.3 million. Working capital was $525.4 million, versus $710.6 million. Management believes available cash, investments and investment income will fund projected requirements for at least 12 months after issuance of the financial statements; it cautions that estimates depend on assumptions and additional capital may be needed. The filing excerpt refers to 2024 revenue and net-cash-use guidance but does not provide clear numeric values.
Year-end borrowings were $607.4 million net carrying value; the filing separately cites $617.5 million of debt recorded. This includes $540.0 million principal of 3.5% convertible notes due 2027, $21.1 million principal of 4.0% notes due 2026, and the Royalty Pharma loan. Royalty participation liabilities were $380.0 million. The company raised $164.2 million net through its ATM equity offering in 2023; it also sold shares for $93.6 million net during January 1–February 27, 2024. Equity issuance and note conversion may dilute shareholders. No income tax provision was recorded, and deferred tax assets remain fully offset by a valuation allowance.
Material developments and outlook
- Aficamten: In December 2023, the Phase 3 SEQUOIA-HCM trial in obstructive HCM met its primary endpoint, improving peak oxygen uptake versus placebo by 1.74 mL/kg/min (p=0.000002); all 10 prespecified secondary endpoints were reported statistically significant. The company described tolerability as comparable to placebo, while noting more patients on aficamten had observed LVEF below 50%. MAPLE-HCM and ACACIA-HCM were enrolling; FOREST-HCM continued long-term follow-up. Management described a potential U.S. launch as early as 2025, dependent on further results and regulatory approval.
- Omecamtiv mecarbil: FDA issued a Complete Response Letter in February 2023, stating GALACTIC-HF was not sufficiently persuasive and that an additional clinical trial was required. FDA denied the company’s appeal in November and reaffirmed the CRL. The EU application remained under review; Ji Xing withdrew its China NDA, with potential resubmission subject to favorable regulatory feedback.
- Other programs: The company discontinued the Phase 3 COURAGE-ALS trial of reldesemtiv and its extension in March 2023 after a futility determination. CK-586 and CK-136 were in Phase 1 development.
- Funding and royalties: Positive SEQUOIA-HCM results made $75 million of Royalty Pharma tranche 4 loans available, subject to the agreement’s terms and minimum draw. Up to $100 million of tranche 5 remains tied to FDA acceptance of an aficamten NDA by the specified deadline. Aficamten royalties sold to Royalty Pharma are generally 4.5% of annual worldwide net sales up to $1 billion and 3.5% above that threshold. The company’s royalty-liability estimates rely on highly uncertain commercialization and sales assumptions.
- Risks and contingencies: Key risks include clinical and regulatory uncertainty, patient enrollment and trial delays, dependence on contract manufacturers and CROs, competition and reimbursement access, future financing needs, debt and royalty obligations, and intellectual-property challenges. A European patent opposition concerning omecamtiv mecarbil is ongoing; the company reported no material legal proceedings.
- Governance and audit: The auditor gave an unqualified opinion on the financial statements and internal controls; the measurement of Royalty Pharma liabilities was identified as a critical audit matter. The CFO resigned effective February 23, 2024, and the CEO assumed principal financial officer duties on an interim basis while a replacement search proceeds.
Important facts for investors to verify
- Full SEQUOIA-HCM results, safety details and regulatory plans, plus enrollment and milestones for MAPLE-HCM and ACACIA-HCM.
- Whether aficamten meets the requirements and timing for an NDA submission, potential approval, REMS obligations and a 2025 launch.
- Any plans, funding and trial design for the additional omecamtiv mecarbil study required by FDA, and the status of the EU review.
- Cash use, numeric 2024 guidance, access to Royalty Pharma loan tranches, and financing needs beyond management’s stated 12-month runway.
- Debt maturities, conversion and dilution exposure, and the sensitivity of the $380.0 million royalty liabilities to changes in sales and launch assumptions.
- Commercial competition, payer coverage and reimbursement prospects for aficamten, and manufacturing readiness for a potential launch.